CureVac NV
0.25 (3.88%)


Draw Mode:

Volume 401,638
Bid Price 6.47
Ask Price 6.88
News -
Day High 6.74


52 Week Range


Day Low 6.53
Company Name Stock Ticker Symbol Market Type
CureVac NV CVAC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.25 3.88% 6.69 19:58:25
Open Price Low Price High Price Close Price Prev Close
6.53 6.53 6.74 6.69 6.44
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,417 401,638 $ 6.68 $ 2,684,560 - 5.63 - 20.20
Last Trade Time Type Quantity Stock Price Currency
18:03:49 10 $ 6.60 USD

CureVac NV Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.49B 221.98M 106.93M $ 117.14M $ -101.94M -2.51 -14.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - -

more financials information »

CureVac NV News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CVAC Message Board. Create One! See More Posts on CVAC Message Board See More Message Board Posts

Historical CVAC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week6.957.016.336.61504,007-0.26-3.74%
1 Month8.608.746.337.31597,802-1.91-22.21%
3 Months6.3112.796.209.651,290,8870.386.02%
6 Months7.8312.795.639.07820,377-1.14-14.56%
1 Year18.8620.205.6311.35675,841-12.17-64.53%
3 Years84.99133.005.6350.62814,198-78.30-92.13%
5 Years84.99133.005.6350.62814,198-78.30-92.13%

CureVac NV Description

CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.